Transformation from adenocarcinoma to squamous cell carcinoma associated with long‑term administration of EGFR‑TKIs

Haruki,Tomohiro; Nakanishi,Atsuyuki; Matsui,Shinji; Kidokoro,Yoshiteru; Kubouchi,Yasuaki; Takagi,Yuzo; Taniguchi,Yuji; Nakamura,Hiroshige

doi:10.3892/mco.2020.2152

Transformation from adenocarcinoma to squamous cell carcinoma associated with long‑term administration of EGFR‑TKIs

Authors:
- Tomohiro Haruki
- Atsuyuki Nakanishi
- Shinji Matsui
- Yoshiteru Kidokoro
- Yasuaki Kubouchi
- Yuzo Takagi
- Yuji Taniguchi
- Hiroshige Nakamura
View Affiliations

Affiliations: Division of General Thoracic Surgery, Faculty of Medicine, Tottori University, Yonago, Tottori 683‑8504, Japan
Published online on: October 9, 2020 https://doi.org/10.3892/mco.2020.2152
Article Number: 82

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although patients with non‑small cell lung cancer exhibiting EGFR mutations generally respond to tyrosine kinase inhibitors (TKIs), the majority of patients acquire resistance ~1 year after treatment. EGFR T790M mutations, MET or HER2 amplifications and phenotypic transformations contribute to the mechanism of EGFR‑TKI resistance. The transformation of small cell lung cancer frequently occurs, although few convert to squamous cell carcinoma associated with the administration of EGFR‑TKIs. The current study reports a case of EGFR‑mutated adenocarcinoma of the lung that transitioned to squamous cell carcinoma in association with long‑term EGFR‑TKIs administration.

View Figures

View References

1	Nagano T, Tachihara M and Nishimura Y: Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells. 7(212)2018.PubMed/NCBI View Article : Google Scholar
2	Oser MG, Niederst MJ, Sequist LV and Engelman JA: Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin. Lancet Oncol. 16:e165–e172. 2015.PubMed/NCBI View Article : Google Scholar
3	Roca E, Pozzari M, Vermi W, Tovazzi V, Baggi A, Amoroso V, Nonnis D, Intagliata S and Berruti A: Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. Lung Cancer. 127:12–18. 2019.PubMed/NCBI View Article : Google Scholar
4	Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3(75ra26)2011.PubMed/NCBI View Article : Google Scholar
5	Hou S, Zhou S, Qin Z, Yang L, Han X, Yao S and Ji H: Evidence, mechanism, and clinical relevance of the transdifferentiation from lung adenocarcinoma to squamous cell carcinoma. Am J Pathol. 187:954–962. 2017.PubMed/NCBI View Article : Google Scholar
6	Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K and Hasegawa Y: An EGFR-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to Afatinib. Intern Med. 57:3429–3432. 2018.PubMed/NCBI View Article : Google Scholar
7	Baldacci S, Kherrouche Z, Cockenpot V, Stoven L, Copin MC, Werkmeister E, Marchand N, Kyheng M, Tulasne D and Cortot AB: MET amplification increases the metastatic spread of EGFR-mutated NSCLC. Lung Cancer. 125:57–67. 2018.PubMed/NCBI View Article : Google Scholar
8	Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M, et al: A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Eur J Cancer. 87:131–139. 2017.PubMed/NCBI View Article : Google Scholar
9	Drilon A, Cappuzzo F, Ou SI and Camidge DR: Targeting MET in lung cancer: Will expectations finally be MET? J Thorac Oncol. 12:15–26. 2017.PubMed/NCBI View Article : Google Scholar